Merck Collaborates with Angiex to Speed Clinical Readiness of New Cancer Therapy

Food and Healthcare Press Releases Wednesday August 30, 2017 08:26
DARMSTADT, Germany--30 Aug--PRNewswire/InfoQuest
  • Project is first for Merck's Massachusetts BioReliance(R) End-to-End Solutions center
  • Collaboration gives Angiex access to Merck's process development tools and technologies

Merck , a leading science and technology company, today announced a new collaboration with Angiex, Inc., Cambridge, Massachusetts, USA to support the biotechnology start-up's ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibody-drug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1.

Photo - https://mma.prnewswire.com/media/548675/Merck_Angiex.jpg

The collaboration with Angiex is the first project to be undertaken at Merck's new biodevelopment center in Massachusetts, USA. Merck will give Angiex access to end-to-end process development tools, education programs and training to support its success.

"Companies benefit from our expertise and experience in developing GMP manufacturing processes for early clinical development programs," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "With an end-to-end approach, Merck can facilitate and accelerate scaling and technical transfer for companies like Angiex."

Angiex CEO Dr. Paul Jaminet applauded Merck's broad range of process development capabilities and services for customers at all stages of molecule development and commercialization. "Through this collaboration, Angiex hopes to accelerate our path to the clinic. We appreciate Merck's expertise in bringing to cancer patients an innovative treatment capable of addressing the most dangerous solid tumors," Jaminet said.

Merck's BioReliance(R) End-to-End Solutions deliver products and services allowing biopharmaceutical companies to accelerate the progression of potential new therapies from the laboratory into clinical trial and on toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot-plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization. To further support its global BioReliance(R) End-to-End Solutions, Merck will inaugurate its new biodevelopment center in Burlington, Massachusetts in October 2017.

Merck's BioReliance(R) End-to-End Solutions is part of the Process Solutions business area within the Life Science business of Merck.
About Angiex

Angiex was founded by world-class scientists to develop vascular-targeted biotherapeutics. Angiex targets fundamental aspects of endothelial biology with a focus on angiogenesis. Angiex's lead product is an antibody-drug conjugate therapy for cancer. Angiex is resident at LabCentral in Cambridge, Massachusetts.

All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

About Merck

Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of EUR15 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the "Merck" name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.


Latest Press Release

Merck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in...

UK Schools Rank Last in Providing Oral Health Education, FDI Survey of 13 Countries Says

Today on World Oral Health Day (WOHD), FDI World Dental Federation (FDI) released the results of a survey from 13 countries, which asked parents with children aged 5–16 if their child's school provided lessons on good oral care. Poor oral health...

Merck Announces Collaboration With Iktos for Generative Artificial Intelligence (AI) Technology

- Collaboration agreement enables Merck access to Iktos AI technology across three drug discovery projects - Generative modelling AI technology enables rapid and cost-effective design of novel drugs - Agreement is part of Merck's R&D strategy to...

Oxford Nanopore Launches Flongle for Rapid, Smaller DNA/RNA Sequencing Tests in Any Environment

Oxford Nanopore has today made Flongle starter packs available to purchase https://store.nanoporetech.com/flongle.html, after initial testing in an early-access programme. Flongle introduces a new paradigm of smaller, on-demand DNA or RNA sequencing...

FDI: Endodontics White Paper Calls for Treatment to Consider Impact on Patient Health and Well-being

FDI World Dental Federation (FDI) released its first white paper on endodontic care today, providing an important resource for dentists, national dental associations (NDAs) and other oral health actors. (Logo:...

Related Topics